UMN Pharma Confirms Immunogenicity and Safety of UMN-0501 Pandemic Influenza Vaccine in Phase I/II Clinical Trials.

Phase I/II clinical trials of UMN-0501, a new pandemic influenza vaccine manufactured from cell culture, were launched in June of 2008. Study results confirmed that UMN-0501 provided immunogenicity in the group administered vaccine without alum against a natural strain of pandemic influenza virus. The tolerability of UMN-0501 was good with no serious or highly adverse side effects diagnosed by the principal investigator.
These results will be released at 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials in February of 2009.